Clinical trials: Bortezomib
B-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia
Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
This pilot, phase II trial studies the side effects of giving bortezomib together with combination chemotherapy and to see how well it works in treating young patients with relapsed acute lymphoblastic leukemia or lymphoblastic…
- Conditions
- B-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma
- Trial name
- NCT00873093
- Testing
- L-asparaginase, doxorubicin hydrochloride, therapeutic hydrocortisone
- Where
- 171 sites in United States, Australia and 2 more
- Volunteers
- 148 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Graft Versus Host Disease
Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft Versus Host Disease
The purpose of this research study is to determine the effectiveness of bortezomib (Velcade) plus prednisone for treating chronic graft versus host disease (cGVHD) and the safety of this drug combination in this patient…
- Trial name
- NCT00815919
- Testing
- bortezomib, Prednisone
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Dana-Farber Cancer Institute
Recurrent Mantle Cell Lymphoma
Bortezomib and Lenalidomide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
This phase II trial studies how well bortezomib and lenalidomide work in treating patients with mantle cell lymphoma that has come back after a period of improvement (refractory) or is not responding to treatment (refractory).
- Trial name
- NCT00553644
- Testing
- Bortezomib, Laboratory Biomarker Analysis, Lenalidomide
- Where
- 82 sites in United States
- Volunteers
- 53 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
Clinical Trial of Expanded and Activated Autologous NK Cells to Treat Multiple Myeloma
The purpose of this study is to determine wether activated and expanded autologous Natural Killer cells (NKAEs) are effective in the treatment of patients with multiple myeloma on second or later relapse.
- Trial name
- NK-VS-MM (NCT02481934)
- Testing
- NKAE cells infusion, Lenalidomide, Bortezomib
- Where
- Spain
- Volunteers
- 5 people
- Sponsor
- Joaquín Martínez López, MD, PhD
Kidney Transplantation
Randomized Trial of Induction Therapies in High Immunological Risk Kidney Transplant Recipients
The purpose of this research study is to find out the effects of adding B lymphocyte modulating agents in patients at risk for rejection receiving an anti-rejection (immunosuppressive) regimen of Thymoglobulin® induction with…
- Trial name
- NCT00782821
- Testing
- Rabbit Antithymocyte Globulin, Velcade, Rituxan
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- University of Cincinnati
Relapsed or Refractory Multiple Myeloma
Study of Vorinostat (MK0683), an Histone Deacetylase (HDAC) Inhibitor in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (MK-0683-095)
The purpose of this study is to evaluate the clinical activity of vorinostat in combination with bortezomib in participants with relapsed or refractory multiple myeloma after at least 2 prior treatment regimens.
- Trial name
- NCT00773838
- Testing
- Vorinostat, Bortezomib, Dexamethasone
- Volunteers
- 143 people
- Sponsor
- Merck Sharp & Dohme LLC
Disorder of Transplanted Kidney
Impact of Proteasome Inhibition on Anti-Donor HLA Antibody Production After Kidney Transplantation
The purpose of this study is to see if treating patients who have high levels of donor specific alloantibodies post-transplant with bortezomib might prevent the development of transplant glomerulopathy and preserve allograft…
- Trial name
- NCT01349595
- Testing
- Bortezomib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Mark Stegall
Refractory Plasma Cell Myeloma
Bortezomib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant
This phase II trial studies how well giving bortezomib, lenalidomide, and dexamethasone together works in treating patients with multiple myeloma undergoing stem cell transplant.
- Trial name
- NCT02353468
- Testing
- Bortezomib, Lenalidomide, Dexamethasone
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Colorado, Denver
Melanoma
Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma
The purpose of this study is to determine the safety, tolerability and dose limiting toxicities (DLTs) of VELCADE when administered in combination with interferon-alpha-2b (IFN-α-2b) to patients with metastatic malignant melanoma.
- Trial name
- NCT01462773
- Testing
- Bortezomib, Interferon Alfa-2b
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Multiple Myeloma
Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma
The purpose of this research study is to determine the safety of plerixafor and bortezomib, and the highest dose that can be given to people safely.
- Trial name
- NCT00903968
- Testing
- Plerixafor, bortezomib, Dexamethasone
- Where
- 5 sites in United States
- Volunteers
- 58 people
- Sponsor
- Dana-Farber Cancer Institute
Multiple Myeloma
UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide
Add three drugs, bortezomib, thalidomide, and dexamethasone (VTD) to the high dose chemotherapy regimen immediately before transplant (DPACE/Melphalan) to try to improve myeloma response and acquire longer survival for…
- Trial name
- NCT00574080
- Testing
- Interim/Maintenance Dexamethasone, Induction/Consolidation Dexamethasone, Induction/Consolidation Cisplatin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Arkansas
Stage I Multiple Myeloma, Stage II Multiple Myeloma
Bortezomib Based Consolidation in Multiple Myeloma Patients Completing Stem Cell Transplant
This randomized phase II trial studies how well giving bortezomib with or without combination chemotherapy works as consolidation therapy in patients with newly diagnosed multiple myeloma who have completed stem cell transplant.
- Conditions
- Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Trial name
- NCT01706666
- Testing
- bortezomib, cyclophosphamide, lenalidomide
- Where
- 4 sites in United States
- Volunteers
- 3 people
- Sponsor
- Mayo Clinic
Multiple Myeloma
Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma
The goal of this clinical study is to learn more about the safety and dosing of the study drug, magrolimab, in combination with other anticancer therapies in participants with relapsed/refractory multiple myeloma.
- Trial name
- NCT04892446
- Testing
- Magrolimab, Daratumumab, Pomalidomide
- Where
- 22 sites in United States, Canada and 1 more
- Volunteers
- 36 people
- Sponsor
- Gilead Sciences
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults
This is a phase II study designed to investigate the combination of bortezomib with the mitoxantrone reinduction regimen used in the ALL R3 trial.
- Trial name
- NCT02535806
- Testing
- Velcade, Methotrexate, Methotrexate / Hydrocortisone / Cytarabine
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Children's Mercy Hospital Kansas City
Multiple Myeloma
A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma
The purpose of this study is to determine whether the combination of bevacizumab and bortezomib have increased efficacy in the treatment of relapsed/ refractory multiple myeloma.
- Trial name
- NCT00464178
- Testing
- Bortezomib
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Hackensack Meridian Health
Non-Hodgkins Lymphoma
Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma
The investigators want to find out if the drugs Velcade and temsirolimus given together are effective in treating cancer. Velcade and temsirolimus are each FDA approved individually for certain types of cancer (Velcade for…
- Trial name
- NCT01281917
- Testing
- Velcade, Temsirolimus
- Where
- 18 sites in United States
- Volunteers
- 40 people
- Sponsor
- University of Wisconsin, Madison
Cancer, Multiple Myeloma
Combination High Dose Melphalan and Autologous Peripheral Blood Stem Cell (PBSC) Transplant With Bortezomib for Multiple Myeloma: A Dose and Schedule Finding Study
The goal of this study is to evaluate the safety of melphalan and autologous PBSCT (peripheral blood stem cell transplantation - stem cells that come from your own body) in combination with bortezomib, a new FDA approved drug…
- Trial name
- NCT00793650
- Testing
- Bortezomib, Melphalan, Autologous PBSC Transplant
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Emory University
Waldenstrom's Macroglobulinemia
Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia
The main goal of this clinical research study is to learn if Velcade ® (bortezomib) given with rituximab can help to control WM.
- Trial name
- NCT00492050
- Testing
- Bortezomib, Rituximab, Valacyclovir
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphoma, Follicular Lymphoma
Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZL
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Conditions
- Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma
- Trial name
- NCT00772668
- Testing
- Rituximab, Bortezomib, Cyclophosphamide
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Miami
Multiple Myeloma
A Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (AMBER)
This is a randomized, blinded, placebo-controlled, multicenter, Phase II study designed to provide a preliminary assessment of the safety and efficacy of combining bevacizumab with bortezomib in patients with relapsed or…
- Trial name
- AMBER (NCT00473590)
- Testing
- Bevacizumab, Bortezomib
- Volunteers
- 102 people
- Sponsor
- Genentech, Inc.